Bausch + Lomb Corporation has discontinued development of BL1107 as a topical glaucoma treatment after a randomized Phase 2 study failed to reproduce the visual function improvements seen in an earlier, smaller trial. The NYSE and Toronto Stock Exchange-listed eye health company said the candidate missed its primary endpoint and important secondary functional measures, although it reduced intraocular pressure and produced no new safety signals.
The decision closes the glaucoma chapter of a program that had been positioned as more than another pressure-lowering therapy. BL1107 was being evaluated for its potential to improve or preserve visual function through neurofunctional enhancement and neuroprotection, an area where glaucoma drug development has repeatedly struggled to convert biological rationale into convincing clinical benefit.
Bausch + Lomb is not abandoning the underlying asset entirely. It intends to redirect development toward a sustained-release implant for geographic atrophy, with clinical studies expected to begin in 2028. That strategy preserves part of the rationale behind its 2025 acquisition of Whitecap Biosciences, but it also moves the program into a different disease, delivery route and evidence pathway.
Why does the BL1107 failure matter beyond the loss of another glaucoma eye drop?
Most established glaucoma treatments aim to lower intraocular pressure through prescription medicines, laser procedures or surgery. Reducing pressure can slow further optic nerve damage, but currently available treatments generally cannot reverse vision that has already been lost.
That limitation creates significant interest in neuroprotective therapies capable of preserving retinal ganglion cells or improving their function independently of, or in addition to, pressure reduction. BL1107, previously known as WB007, was a potent alpha-2 adrenergic agonist being developed around that broader ambition.
The Phase 2 results weaken the argument that short-term topical exposure to BL1107 can generate a reproducible improvement in visual function. The drug demonstrated ocular activity because one secondary endpoint showed a reduction in intraocular pressure. However, biological activity is not the same as clinically meaningful differentiation.
That distinction was central to the program. Bausch + Lomb did not need BL1107 merely to behave like another pressure-lowering drop. It needed the candidate to demonstrate that its activity translated into measurable improvements in how patients could see, particularly after earlier findings had suggested a possible neurofunctional effect.
The failure therefore reaches beyond a missed statistical endpoint. It illustrates how difficult it remains to prove that a glaucoma therapy is protecting or restoring neural function rather than simply influencing a familiar physiological marker.
What do the Phase 2 trial design and failed endpoints reveal about the earlier signal?
The randomized, double-masked, three-arm, parallel-group study enrolled 159 adults with primary open-angle glaucoma or ocular hypertension. Two concentrations of BL1107 were evaluated against timolol 0.5 percent over a 28-day treatment period.
The primary endpoint measured change from baseline in visual field mean deviation at Day 28. Mean deviation is a summary measure used to describe how a patient’s visual field differs from an age-adjusted normal field, making it clinically relevant when investigators are attempting to detect changes in glaucoma-related function.
BL1107 did not meet that endpoint. Key secondary measures of visual performance also failed, including low-luminance best-corrected visual acuity responder rates. The absence of supportive findings across more than one functional assessment makes the result harder to explain as an isolated endpoint problem.
The study was designed to reproduce improvements observed in a smaller Phase 1/2a trial. Replication is especially important when an early study has a limited sample and produces an unexpectedly encouraging result. Small trials can be affected by participant selection, baseline imbalances, measurement variability and chance, even when the underlying study is properly conducted.
Visual field testing introduces another layer of difficulty. Patient concentration, fatigue, learning effects and test reliability can influence results, while short studies must distinguish genuine functional change from normal variation. Those challenges do not invalidate visual field endpoints, but they increase the importance of adequate sample size, prespecified analysis and consistency across related measures.
Only topline findings have been disclosed. Without full numerical results, it is not yet possible to judge the magnitude of differences between treatment groups, whether either dose showed a partial trend, how consistent the response was across patients or whether baseline disease severity affected outcomes.
The decision to terminate the topical program suggests that the total dataset did not contain a sufficiently persuasive subgroup, dose-response pattern or secondary signal to justify another expensive confirmatory trial. The absence of new safety concerns removes tolerability as the immediate cause of discontinuation. Efficacy was the decisive issue.
Why was the intraocular-pressure reduction insufficient to keep BL1107 alive?
Meeting an intraocular-pressure endpoint confirms that BL1107 reached and affected its ocular target. In another development program, that result might have provided grounds to continue. For this candidate, it was not enough.
The pressure-lowering glaucoma market already contains multiple drug classes, generic products, fixed-dose combinations, laser treatment options and surgical technologies. A new entrant would need to offer stronger efficacy, better tolerability, easier dosing, improved adherence or another meaningful clinical advantage to justify investment and eventual adoption.
BL1107’s potential value rested heavily on the prospect of improving visual function, not simply reducing pressure. Once the functional endpoints failed, the remaining pressure signal placed the candidate in a much more crowded commercial category.
Continuing development solely as another intraocular-pressure treatment would have required Bausch + Lomb to establish a new competitive thesis. The company would have needed to show that BL1107 could outperform or materially complement established therapies, while funding additional studies and accepting the opportunity cost of keeping an uncertain program alive.
Discontinuation is therefore a rational capital-allocation decision rather than evidence that BL1107 had no pharmacological activity. The compound did something measurable in the eye. It did not demonstrate the effect required to support its intended positioning as a neuroprotective or neuroenhancing glaucoma therapy.
For clinicians and researchers, the mismatch between intraocular-pressure reduction and functional outcomes is also instructive. It reinforces the need to distinguish surrogate activity from evidence that a therapy is changing the patient experience or altering the course of optic nerve damage.
Can the sustained-release geographic atrophy implant avoid the problems seen in glaucoma?
Bausch + Lomb acquired Whitecap Biosciences in January 2025 to add programs for glaucoma and geographic atrophy to its ophthalmology pipeline. The company has since indicated that the principal strategic attraction was the opportunity to develop a sustained-release implant for geographic atrophy.
Geographic atrophy is an advanced form of dry age-related macular degeneration that causes progressive loss of retinal tissue and vision. Bausch + Lomb intends to collaborate with Ripple Therapeutics on an implant using a controlled-release platform that chemically engineers drugs to release over time without relying on a conventional polymer matrix.
The change in direction does not amount to a simple reformulation of the failed glaucoma drop. The implant would target a different retinal disease, produce different exposure characteristics and require its own preclinical, manufacturing, surgical-delivery and clinical evidence package.
Failure in glaucoma does not automatically prove that the compound will fail in geographic atrophy. Disease biology, tissue exposure, dosing duration and therapeutic objectives may differ considerably. Sustained local delivery could also produce concentrations and treatment duration that cannot be achieved through daily topical administration.
However, the geographic atrophy strategy remains early and highly uncertain. Clinical trials are not expected to begin until 2028, leaving Bausch + Lomb with a substantial period of formulation development, toxicology work and regulatory preparation before meaningful human efficacy data become available.
The implant will also face a different competitive environment. Geographic atrophy drug development is increasingly focused on slowing lesion growth, improving durability and reducing the treatment burden associated with repeated intravitreal administration. A sustained-release product could be attractive, but only if its safety, release profile and clinical effect justify an implant-based approach.
Investors should therefore treat the geographic atrophy program as a separate, long-duration option rather than an immediate rescue of BL1107. The glaucoma failure has removed the nearer-term validation opportunity, while the implant’s commercial potential remains dependent on evidence that is still several years away.
How significant is the setback for Bausch + Lomb’s broader ophthalmology pipeline?
Bausch + Lomb has said its development portfolio contains more than 60 assets across its Consumer, Pharmaceuticals, Surgical and Vision Care businesses. That diversification limits the financial impact of any single clinical failure and differentiates the company from a smaller biotechnology developer whose valuation may depend heavily on one experimental therapy.
The company entered the setback with underlying commercial momentum. First-quarter 2026 revenue increased 9 percent on a reported basis to $1.244 billion, while Pharmaceuticals revenue grew 14 percent. Bausch + Lomb also raised its full-year revenue and adjusted earnings guidance after the quarter.
Those operating results provide some insulation, but the failure still matters for pipeline credibility. BL1107 had been presented as an opportunity to move glaucoma treatment beyond conventional pressure management. Its discontinuation eliminates a potentially differentiated pharmaceutical asset and reduces the likelihood of a nearer-term neuroprotection franchise.
The market response reflected that balance. Bausch + Lomb shares closed at $16.23 on July 10, down 2.99 percent during the first regular trading session after the announcement. The stock had also fallen in extended trading when the findings were released.
At the July 10 close, the shares were approximately 5.4 percent below their July 2 level, but about 6.4 percent above the June 10 closing price. They remained within a 52-week range of $13.09 to $18.92.
That price action indicates disappointment without suggesting that investors view BL1107 as fundamental to Bausch + Lomb’s entire valuation. The company’s established contact lens, surgical and pharmaceutical operations remain more important to near-term financial performance. The failed trial is more likely to be interpreted as a lost pipeline option and a reminder of research risk than as a threat to current revenue.
Bausch + Lomb’s second-quarter results, scheduled for July 29, will give investors a nearer-term opportunity to assess whether growth in commercial products can continue offsetting pipeline volatility.
What evidence will determine whether the remaining BL1107 strategy retains value?
Full disclosure of the Phase 2 dataset will be important. Glaucoma researchers will want to see the performance of each dose, the size and variability of visual field changes, the magnitude of pressure reduction, test reliability criteria and whether any functional trends appeared in prespecified patient groups.
The results may also influence how future glaucoma neuroprotection trials are designed. A 28-day study can test rapid neurofunctional enhancement, but demonstrating durable neuroprotection may require longer follow-up and endpoints capable of separating true disease modification from short-term measurement fluctuation.
For Bausch + Lomb, attention now shifts to the geographic atrophy implant’s development timetable. Progress in formulation, preclinical safety, manufacturing reproducibility and regulatory discussions will determine whether the 2028 clinical target remains realistic.
The company must also clarify whether the implant is expected to deliver the same active compound used in the glaucoma study, how sustained exposure is intended to affect geographic atrophy biology and what advantages the proposed implant could offer over competing retinal treatments.
BL1107’s pressure-lowering activity shows that the molecule was not pharmacologically inactive. Yet the Phase 2 study asked a more consequential question, whether that activity could translate into better visual function for people with glaucoma. The answer was not strong enough to support further development.
Bausch + Lomb has responded by ending the weaker program rather than extending it through another uncertain trial. The geographic atrophy implant keeps the acquired technology alive, but it resets the scientific and investment clock. Its next opportunity to create meaningful evidence will arrive much later, in a different disease and under a substantially different development strategy.
Research was verified using the company’s July 9 Phase 2 disclosure, trial registration and ophthalmology references, along with current market and financial data. The formatting follows the uploaded PDN editorial specification.
